Search results for "CARDIOMYOPATHY"

showing 10 items of 242 documents

Familial fatal fetal cardiomyopathy with isolated myocardial calcifications: A new syndrome?

2001

We describe three male sib fetuses with isolated myocardial calcifications resulting in intrauterine fetal death (IUFD) as early as the second trimester. No evidence for an underlying mitochondrial cytopathy, dystrophinopathy or myopathy was found. There were no signs of inflammation or a metabolic disorder, and the mother had no prenatal exposure of teratogenic drugs. Furthermore, no mutation in the Barth syndrome gene (G4.5) could be detected. Because isolated calcification of the heart and IUFD are not typical of any previously described inherited cardiomyopathy, it may represent a new familial fetal cardiomyopathy.

MaleMyocardial calcificationPathologymedicine.medical_specialtyHeart diseaseCardiomyopathyUltrasonography PrenatalFatal OutcomeFetusPregnancymedicineHumansMyopathyFetal DeathGenetics (clinical)Family HealthFetusbusiness.industryMyocardiumMetabolic disorderCalcinosisBarth syndromeSyndromemedicine.diseasePregnancy ComplicationsFetal DiseasesPregnancy Trimester Secondembryonic structuresFemalemedicine.symptomCardiomyopathiesbusinessCalcificationAmerican Journal of Medical Genetics
researchProduct

Interferon-γ Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice

2007

Chronic heart failure is associated with an activation of the immune system characterized among other factors by the cardiac synthesis and serum expression of proinflammatory cytokines. There is unequivocal clinical and experimental evidence that the cytokine tumor necrosis factor-alpha is involved in the development of chronic heart failure, but a putative cardiotoxic potential of the proinflammatory cytokine interferon (IFN)-gamma remains primarily unknown. To investigate this issue we analyzed the cardiac phenotype of SAP-IFN-gamma transgenic mice, which constitutively express IFN-gamma in their livers and hence exhibit high circulating serum levels of this cytokine. SAP-IFN-gamma mice s…

MaleMyocarditismedicine.medical_treatmentT-LymphocytesCardiomyopathyGene ExpressionMice Inbred StrainsMice Transgenic030204 cardiovascular system & hematologyBiologyPathology and Forensic MedicineProinflammatory cytokine03 medical and health sciencesInterferon-gammaMice0302 clinical medicinemedicineAnimalsHumansInterferon gammaIntestinal MucosaPromoter Regions Genetic030304 developmental biology0303 health sciencesCardiotoxicityReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaMacrophagesHeartDendritic Cellsmedicine.diseaseInterleukin-123. Good healthRatsIntestinesMice Inbred C57BLMyocarditisSerum Amyloid P-ComponentCytokineEchocardiographyImmunologyChronic DiseaseInterleukin 12Tumor necrosis factor alphaFemaleCardiomyopathiesmedicine.drugRegular Articles
researchProduct

Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome

2022

ObjectiveThe advantage of beta-blockers has been postulated in patients with Takotsubo syndrome (TTS) given the pathophysiological role of catecholamines. We hypothesised that beta-blocker treatment after discharge may improve the long-term clinical outcome in this patient population.MethodsThis was an observational, multicentre study including consecutive patients with TTS diagnosis prospectively enrolled in the Takotsubo Italian Network (TIN) register from January 2007 to December 2018. TTS was diagnosed according to the TIN, Heart Failure Association and InterTAK Diagnostic Criteria. The primary study outcome was the occurrence of all-cause death at the longest available follow-up; secon…

MaleOutcome AssessmentAdrenergic beta-AntagonistsShockCardiogenicHealth CareTinTakotsubo CardiomyopathyHypertensionOutcome Assessment Health CareHumansFemaleCardiomyopathiesCardiology and Cardiovascular MedicineCardiomyopathies; Hypertension; Outcome Assessment Health Care; Adrenergic beta-Antagonists; Aged; Female; Humans; Male; Shock Cardiogenic; Tin; Hypertension; Takotsubo CardiomyopathyAgedHeart
researchProduct

Risk Stratification Using the CHA(2)DS(2)-VASc Score in Takotsubo Syndrome: Data From the Takotsubo Italian Network

2017

Background The CHA 2 DS 2 ‐VASc score predicts stroke in patients with atrial fibrillation and has been reported to have a prognostic role even in acute coronary syndrome patients. The Takotsubo syndrome is a condition that mimics acute coronary syndrome and may present several complications including stroke. We sought to assess the ability of CHA 2 DS 2 ‐VASc score to predict adverse events in Takotsubo syndrome patients. Methods and Results Overall, 371 Takotsubo syndrome patients were enrolled in a prospective registry. Patients were divided into 3 groups according to the CHA 2 DS 2 ‐VASc score: Group A (≤1), B (2–3), and C (≥4). The median CHA 2 DS 2 ‐VASc score was 3 (interquartile ra…

MalePediatricsArrhythmias030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk FactorsInterquartile rangeOdds RatioCoronary Heart DiseaseProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionDSStrokeTakotsuboOriginal ResearchIncidenceMortality rateanticoagulant cardiovascular events CHA2DS2-VASc score stroke Takotsubo Takotsubo cardiomyopathy. Takotsubo syndromeAtrial fibrillationMiddle AgedPrognosisAnticoagulant; Cardiovascular events; CHA2DS2-VASc score; Stroke; Takotsubo; Takotsubo cardiomyopathy; Takotsubo syndrome; Cardiology and Cardiovascular MedicineStrokeItalyCardiologyFemaleCHA2DS2‐VASc scoreTakotsubo syndromeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeCHA2DS2-VASc scoreCardiomyopathy2Cardiovascular eventRisk Assessment-VASc scorecardiovascular events03 medical and health sciencesInternal medicinemedicineHumansAgedbusiness.industryAnticoagulantAnticoagulantsThrombosisOdds ratiomedicine.diseaseCHA2DS2–VASc scoreCHACerebrovascular Disease/StrokeTakotsubo cardiomyopathybusinessFollow-Up Studies
researchProduct

Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry

2019

Background Current literature only reports variable information from single‐center studies on the recurrence rate, the complications, and the outcome of patients with Takotsubo syndrome ( TTS) experiencing recurrent TTS . Therefore, a detailed description of clinical characteristics, predictors, and the prognostic impact of patients with TTS and recurrences in a multicenter registry is needed. Methods and Results We analyzed 749 patients with TTS from 9 European centers being part of the international, multicenter GEIST (German Italian Stress Cardiomyopathy) Registry. Patients were divided into the recurrence group and the nonrecurrence group. The recurrence rate at a median follow‐up of 8…

MalePediatricsmedicine.medical_specialtyrecurrenceCardiomyopathyVentricular Dysfunction RightShock Cardiogenic030204 cardiovascular system & hematology03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineTakotsubo CardiomyopathyGermanyThromboembolismMedicineHumans030212 general & internal medicineHospital MortalityRegistriesOriginal ResearchAgedProportional Hazards ModelsHeart FailureAged 80 and overTakotsubo syndromebusiness.industryIncidence (epidemiology)IncidenceStroke VolumeMiddle Agedmedicine.diseaseStrokeItalyBackground currentHeart failureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry.

2019

Introduction and objectives: There is current controversy regarding the benefits of percutaneous recanalization (PCI) of chronic total coronary occlusions (CTO). Our aim was to determine acute and follow-up outcomes in our setting. Methods: Two-year prospective registry of consecutive patients undergoing PCI of CTO in 24 centers. Results: A total of 1000 PCIs of CTO were performed in 952 patients. Most were symptomatic (81.5%), with chronic ischemic heart disease (59.2%). Previous recanalization attempts had been made in 15%. The mean SYNTAX score was 19.5 +/- 10.6 and J-score was > 2 in 17.3%. A retrograde procedure was performed in 92 patients (9.2%). The success rate was 74.9% and was hi…

MaleReoperationmedicine.medical_specialtyPercutaneousmedicine.medical_treatmentPerforation (oil well)Myocardial Ischemia030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary InterventionPostoperative Complications0302 clinical medicineInternal medicineMyocardial RevascularizationmedicineHumansProspective StudiesRegistriesMyocardial infarctionProspective cohort studyUltrasonography InterventionalAgedPortugalbusiness.industryMortality ratePercutaneous coronary interventionGeneral Medicinemedicine.diseaseTreatment OutcomeCoronary OcclusionSurgery Computer-AssistedSpainCoronary occlusionChronic DiseaseConventional PCICardiologyFemaleCTO Cardiopatía isquémica crónica Chronic ischemic cardiomyopathy Chronic total occlusions IVUS OCT Oclusiones crónicasbusiness
researchProduct

Gender differences in takotsubo syndrome

2022

Background: Male sex in takotsubo syndrome (TTS) has a low incidence and it is still not well characterized. Objectives: The aim of the present study is to describe TTS sex differences. Methods: TTS patients enrolled in the international multicenter GEIST (GErman Italian Spanish Takotsubo) registry were analyzed. Comparisons between sexes were performed within the overall cohort and using an adjusted analysis with 1:1 propensity score matching for age, comorbidities, and kind of trigger. Results: In total, 286 (11%) of 2,492 TTS patients were men. Male patients were younger (age 69 ± 13 years vs 71 ± 11 years; P = 0.005), with higher prevalence of comorbid conditions (diabetes mellitus 25% …

MaleSex Characteristicsmale sexcardiogenic shockShock CardiogenicSexotakotsuboChoque cardiogénicoSex FactorsTakotsubo CardiomyopathyPrevisiónfollow-upgenderHumansFemaleCardiomiopatía de TakotsuboprognosisRegistriesCardiology and Cardiovascular MedicineSistema cardiovascular
researchProduct

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

2016

Tafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects h…

MaleTafamidisAmyloid polyneuropathyNeurologyCardiomyopathyDisease030204 cardiovascular system & hematologySeverity of Illness IndexTransthyretinchemistry.chemical_compound0302 clinical medicinePrealbuminTafamidiLongitudinal StudiesStage (cooking)Aged 80 and overBenzoxazolesbiologyAmyloidosisMiddle Agedamyloid polyneuropathy; tafamidis; transthyretinPrognosisTafamidisSettore MED/26 - NEUROLOGIATreatment OutcomeItalyNeurologyDisease ProgressionFemaleAmyloid polyneuropathy; Tafamidis; Transthyretin; Neurology (clinical); NeurologyAdultmedicine.medical_specialty03 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansAgedAmyloid Neuropathies Familialbusiness.industrynutritional and metabolic diseasesmedicine.diseaseSurgeryTransthyretinchemistryMutationbiology.proteinNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurology
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct